Pfizer has begun an early stage trial of an experimental vaccine against respiratory syncytial virus (RSV) in healthy adult volunteers. Pfizer is aiming to develop the vaccine for populations at highest risk of the respiratory infection, primarily infants through maternal immunisation and older adults through direct vaccination. The Phase I/II, randomised, placebo-controlled, observer-blind, dose-ranging study
New scheme being tested by the NHS that considers the mental health of patients with long-term conditions has recently been hailed a success, for having reduced related hospital admissions by some 75%. It was noted that those with a physical health condition are more likely than the rest of the population to experience mental ill
The public health body has unveiled new process that is designed to fast track clinical trials undertaken across the NHS, and to also boost access for patients. Collaborating with the NIHR, Health Research Authority and NHS Improvement, NHS England said it will bring in new measures that “eliminate variation and delays” in organising commercial contract
CRUK has launched its new Brain Tumour Awards in partnership with The Brain Tumour Charity. The awards were launched to aid advancing understanding about the biology of the disease and the challenges translating discoveries into treatments. Research teams around the UK can now apply for grants up to £10 million for each project over five
Pfizer treats first patient in trial for investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular dystrophy
Pfizer has stated that they have begun their Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in patients with Duchenne muscular dystrophy (DMD). The first patient received an infusion of the mini-dystrophin gene, administered under the supervision of principal investigator, Edward Smith, MD, Associate Professor of Pediatrics and Neurology at Duke University
Yvette Cleland comments on the latest Clinical Professionals Industry Analytics report, “What do we expect the impact of the EMA leaving the UK to be?” “The Dutch government’s successful bid to host the European Medicines Agency (EMA) has already faced its first hurdle, the temporary offices in which it was proposed to house some staff
NICE has turned down NHS funding for Roche’s Alecensa as a first-line treatment for lung cancer. The public regulatory body denied the drug for untreated ALK-positive advanced non-small-cell lung cancer (NSCLC) in adults. Alecensa was approved Europe late last year after Phase III trial data showed median progression-free survival of 25.7 months for people given
NHS England has stated it will be funding a pioneering procedure that will improve treatment outcomes for patients with a lung disease called Chronic Thromboembolic Pulmonary Hypertension (CTEPH). The condition involves chronic blood clots block blood flow in the arteries, raising pressure in the lung, which can cause heart failure and premature death. Patients with
Health secretary Jeremy Hunt goes against the long-standing government policy on NHS funding, calling for a 10 year funding settlement for the health service. He added that ministers needed to be open to the idea of “innovative forms of taxation” to end the “feast and famine” funding of the NHS over the last 20 years.
The National Institute for Health Research (NIHR) has launched a set of new national standards for members of the public involved in clinical research, that will be used by organisations across the UK. The six standards aim to provide accurate benchmarks for effective public involvement, alongside indicators against which improvement can be monitored, it said.